Andrew Hoffman, MD
Endocrinology, Diabetes & Metabolism · Stanford, CANPI 1619924685
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $49,699 of the $62,776 with a category attached, or 79.2%. Novo Nordisk accounts for 62.2% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2020 at $22,152 and has fallen 57.8% since, to $9,355 in 2025. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 43 payments — averaging $1459.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$39K
- Ascendis Pharma Endocrinology Inc$23K
- Eagle Pharmaceuticals, Inc.$500
Across 1 payment — averaging $14,343 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$14K
What the payments were for
- Consulting fees$49,69979%
- Speaking & faculty fees$7,59612%
- Travel & lodging$4,9688%
- Food & beverage$5131%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $39,073 |
| Ascendis Pharma Endocrinology Inc | 7 | $23,203 |
| Eagle Pharmaceuticals, Inc. | 1 | $500 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Norditropin$32,003
- SKYTROFA$23,135
- Macrilen$6,090
How this compares
$62,776 in reported general payments places this provider in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OmnitropeSomatropin | 12 | $7,537 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Stanford
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.